Product Code: A15447
The global hepatitis E diagnostic tests market was valued at $61.69 million in 2021, and is projected to reach $93.5 million by 2031, registering a CAGR of 4.2% from 2022 to 2031.
Hepatitis E is a type of viral infection which leads to liver inflammation caused due to hepatitis E virus (HEV). Hepatitis E virus is a positive-sense, single-stranded, non-enveloped, RNA icosahedral virus and is one of the five known human hepatitis virus (A, B, C, D, and E). The transmission of hepatitis E infection occurs through oral or fecal route which is similar to that of hepatitis A. This condition is temporary and can be treated and recovered if diagnosed at an early stage. However, the infection may lead to serious effects in pregnant women and people with weak immune system, which may further lead to death.
Symptoms of hepatitis E infection are asymptomatic in acute cases, however in some cases the patient may suffer from jaundice, fatigue and nausea. It also includes chronic conditions such as fulminant liver failure or liver cirrhosis which are mainly seen in patients with weakened immune systems and who had a solid organ transplant. There is need for early detection and treatment of the infection, which leads to rise in demands for hepatitis E diagnostics kits as the condition may be life threatening in some cases.
According to World Health Organization (WHO), thousands of acute viral hepatitis infections affect children, adolescents and adults every year which may cause mild diseases and even go undetected. However, in some cases, they can cause severe complications and lead to the death of the person.
It also states that in 2019 alone, an estimated 78,000 deaths occurred due to complications of acute hepatitis A to E infections around the globe. This highlights the rise in number of hepatitis infections in population, which further demands for early diagnosis of the condition. This further propels the sale of hepatitis E diagnostic test kits and subsequently the growth of hepatitis E diagnostic tests market.
Furthermore, certain group of population is at high risk of hepatitis E infection, which includes pregnant women, immunosuppressed people, and people with pre-existing liver disease. Pregnant women are majorly at higher risk of getting HEV genotype 1 infection which is associated with fulminant hepatitis and leads to death in women. In addition, women in second or third trimester are at higher risk of acute liver failure, fetal loss and mortality due to hepatitis E. World Health Organization further states that up to 20-25% of pregnant women can die due to hepatitis E in third trimester of pregnancy. Thus, efficient diagnosis and treatment of the condition is necessary to reduce the mortality rate in pregnant women associated with hepatitis E, which propels the growth of hepatitis E diagnostic tests market.
Furthermore, advancements in the field of diagnosis and treatments drive the market. Several advancements have been done by the researchers and manufacturers in healthcare sector which makes the diagnosis and treatment procedure more efficient and accurate. The development of nucleic acid testing kits and enzyme-linked immunosorbent assay (ELISA) kits, which is based on the detection of specific anti-HEV immunoglobulin M (IgM) antibodies to the virus in the blood of a person, offers high quality, efficiency and accuracy in results. For instance, Human Hepatitis E Virus Antibody (IgG) ELISA Kit offered by Cusabio Technology Llc. is used in the detection of HEV IgG antibody in the serum and plasma and is based on qualitative enzyme immunoassay technique.
Such, new and advanced diagnostic tests kits offered by manufacturers increase the demand for the hepatitis E diagnostics tests kits and accelerate the market growth.Furthermore, rise in funds by governments of various countries and non-government organizations to initiate manufacturing units in the healthcare sector are expected to boost the market growth. Moreover, acquisition and partnerships strategies adopted by key market players are boosting factors for the market.
However, hepatitis E diagnostic kits have limited shelf life. Therefore, there is a crucial need to manage the storage of these kits. In addition, these ELISA kits are to be handled with care, as minor changes in the kit may lead to inaccuracies in range, sensitivity, and precision which provides hindrance to the hepatitis E diagnostic tests market growth. On the contrary, rise in the research and development activities by the key market players and increase in healthcare expenditure have further encouraged many key players to enter emerging markets, thus offering lucrative opportunities for the expansion of the hepatitis E diagnostic tests market.
The hepatitis E diagnostic tests market is segmented on the basis of, test type, end user and region. On the basis of test type, the market is categorized into HEV IgM ELISA Test, HEV IgG ELISA Test, and RT-PCR Test. On the basis of end user, it is segmented into hospitals, diagnostic centers and others (research centers, blood bank, point of care, standalone laboratories). On the basis of region, it is studied across North America, Europe, Asia-Pacific, and LAMEA.
Some of the major companies that operate in the global hepatitis E diagnostic tests market are Altona Diagnostics GmbH, Beijing Wantai Biological Pharmacy Enterprise Co.,Ltd, Dia.Pro Diagnostic Bioprobes s.r.l, ELITechGroup, PerkinElmer Inc. (Euroimmun Medizinische Labordiagnostika AG), F. Hoffmann-La Roche Ltd., Fortress Diagnostics, Mikrogen Diagnostik, MP Biomedicals , Primerdesign Ltd. and others.
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the hepatitis e diagnostic tests market analysis from 2021 to 2031 to identify the prevailing hepatitis e diagnostic tests market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the hepatitis e diagnostic tests market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global hepatitis e diagnostic tests market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Test Type
- ELISA HEV IgM Test
- ELISA HEV IgG Test
- RT-PCR Test
By End User
- Hospitals
- Diagnostic Centers
- Others
By Region
- North America
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
- Key Market Players
- MP Biomedicals LLP
- F. Hoffmann-La Roche Ltd.
- Altona Diagnostics
- PerkinElmer, Inc
- Dia.Pro - Diagnostic Bioprobes s.r.l
- Primerdesign Ltd
- Mikrogen GmbH
- Fortress Diagnostics
- ELITechGroup
- Beijing Wantai Biolog Pha Ent Co Ltd
TABLE OF CONTENTS
CHAPTER 1:INTRODUCTION
- 1.1.Report description
- 1.2.Key market segments
- 1.3.Key benefits to the stakeholders
- 1.4.Research Methodology
- 1.4.1.Secondary research
- 1.4.2.Primary research
- 1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
- 2.1.Key findings of the study
- 2.2.CXO Perspective
CHAPTER 3:MARKET OVERVIEW
- 3.1.Market definition and scope
- 3.2.Key findings
- 3.2.1.Top investment pockets
- 3.3.Porter's five forces analysis
- 3.4.Market dynamics
- 3.4.1.Drivers
- 3.4.2.Restraints
- 3.4.3.Opportunities
- 3.5.COVID-19 Impact Analysis on the market
CHAPTER 4: HEPATITIS E DIAGNOSTIC TESTS MARKET, BY TEST TYPE
- 4.1 Overview
- 4.1.1 Market size and forecast
- 4.2. ELISA HEV IgM Test
- 4.2.1 Key market trends, growth factors and opportunities
- 4.2.2 Market size and forecast, by region
- 4.2.3 Market share analysis by country
- 4.3. ELISA HEV IgG Test
- 4.3.1 Key market trends, growth factors and opportunities
- 4.3.2 Market size and forecast, by region
- 4.3.3 Market share analysis by country
- 4.4. RT-PCR Test
- 4.4.1 Key market trends, growth factors and opportunities
- 4.4.2 Market size and forecast, by region
- 4.4.3 Market share analysis by country
CHAPTER 5: HEPATITIS E DIAGNOSTIC TESTS MARKET, BY END USER
- 5.1 Overview
- 5.1.1 Market size and forecast
- 5.2. Hospitals
- 5.2.1 Key market trends, growth factors and opportunities
- 5.2.2 Market size and forecast, by region
- 5.2.3 Market share analysis by country
- 5.3. Diagnostic Centers
- 5.3.1 Key market trends, growth factors and opportunities
- 5.3.2 Market size and forecast, by region
- 5.3.3 Market share analysis by country
- 5.4. Others
- 5.4.1 Key market trends, growth factors and opportunities
- 5.4.2 Market size and forecast, by region
- 5.4.3 Market share analysis by country
CHAPTER 6: HEPATITIS E DIAGNOSTIC TESTS MARKET, BY REGION
- 6.1 Overview
- 6.1.1 Market size and forecast
- 6.2 North America
- 6.2.1 Key trends and opportunities
- 6.2.2 North America Market size and forecast, by Test Type
- 6.2.3 North America Market size and forecast, by End User
- 6.2.4 North America Market size and forecast, by country
- 6.2.4.1 U.S.
- 6.2.4.1.1 Key market trends, growth factors and opportunities
- 6.2.4.1.2 Market size and forecast, by Test Type
- 6.2.4.1.3 Market size and forecast, by End User
- 6.2.4.2 Canada
- 6.2.4.2.1 Key market trends, growth factors and opportunities
- 6.2.4.2.2 Market size and forecast, by Test Type
- 6.2.4.2.3 Market size and forecast, by End User
- 6.2.4.3 Mexico
- 6.2.4.3.1 Key market trends, growth factors and opportunities
- 6.2.4.3.2 Market size and forecast, by Test Type
- 6.2.4.3.3 Market size and forecast, by End User
- 6.3 Europe
- 6.3.1 Key trends and opportunities
- 6.3.2 Europe Market size and forecast, by Test Type
- 6.3.3 Europe Market size and forecast, by End User
- 6.3.4 Europe Market size and forecast, by country
- 6.3.4.1 Germany
- 6.3.4.1.1 Key market trends, growth factors and opportunities
- 6.3.4.1.2 Market size and forecast, by Test Type
- 6.3.4.1.3 Market size and forecast, by End User
- 6.3.4.2 France
- 6.3.4.2.1 Key market trends, growth factors and opportunities
- 6.3.4.2.2 Market size and forecast, by Test Type
- 6.3.4.2.3 Market size and forecast, by End User
- 6.3.4.3 UK
- 6.3.4.3.1 Key market trends, growth factors and opportunities
- 6.3.4.3.2 Market size and forecast, by Test Type
- 6.3.4.3.3 Market size and forecast, by End User
- 6.3.4.4 Italy
- 6.3.4.4.1 Key market trends, growth factors and opportunities
- 6.3.4.4.2 Market size and forecast, by Test Type
- 6.3.4.4.3 Market size and forecast, by End User
- 6.3.4.5 Spain
- 6.3.4.5.1 Key market trends, growth factors and opportunities
- 6.3.4.5.2 Market size and forecast, by Test Type
- 6.3.4.5.3 Market size and forecast, by End User
- 6.3.4.6 Rest of Europe
- 6.3.4.6.1 Key market trends, growth factors and opportunities
- 6.3.4.6.2 Market size and forecast, by Test Type
- 6.3.4.6.3 Market size and forecast, by End User
- 6.4 Asia-Pacific
- 6.4.1 Key trends and opportunities
- 6.4.2 Asia-Pacific Market size and forecast, by Test Type
- 6.4.3 Asia-Pacific Market size and forecast, by End User
- 6.4.4 Asia-Pacific Market size and forecast, by country
- 6.4.4.1 Japan
- 6.4.4.1.1 Key market trends, growth factors and opportunities
- 6.4.4.1.2 Market size and forecast, by Test Type
- 6.4.4.1.3 Market size and forecast, by End User
- 6.4.4.2 China
- 6.4.4.2.1 Key market trends, growth factors and opportunities
- 6.4.4.2.2 Market size and forecast, by Test Type
- 6.4.4.2.3 Market size and forecast, by End User
- 6.4.4.3 Australia
- 6.4.4.3.1 Key market trends, growth factors and opportunities
- 6.4.4.3.2 Market size and forecast, by Test Type
- 6.4.4.3.3 Market size and forecast, by End User
- 6.4.4.4 India
- 6.4.4.4.1 Key market trends, growth factors and opportunities
- 6.4.4.4.2 Market size and forecast, by Test Type
- 6.4.4.4.3 Market size and forecast, by End User
- 6.4.4.5 South Korea
- 6.4.4.5.1 Key market trends, growth factors and opportunities
- 6.4.4.5.2 Market size and forecast, by Test Type
- 6.4.4.5.3 Market size and forecast, by End User
- 6.4.4.6 Rest of Asia-Pacific
- 6.4.4.6.1 Key market trends, growth factors and opportunities
- 6.4.4.6.2 Market size and forecast, by Test Type
- 6.4.4.6.3 Market size and forecast, by End User
- 6.5 LAMEA
- 6.5.1 Key trends and opportunities
- 6.5.2 LAMEA Market size and forecast, by Test Type
- 6.5.3 LAMEA Market size and forecast, by End User
- 6.5.4 LAMEA Market size and forecast, by country
- 6.5.4.1 Brazil
- 6.5.4.1.1 Key market trends, growth factors and opportunities
- 6.5.4.1.2 Market size and forecast, by Test Type
- 6.5.4.1.3 Market size and forecast, by End User
- 6.5.4.2 Saudi Arabia
- 6.5.4.2.1 Key market trends, growth factors and opportunities
- 6.5.4.2.2 Market size and forecast, by Test Type
- 6.5.4.2.3 Market size and forecast, by End User
- 6.5.4.3 South Africa
- 6.5.4.3.1 Key market trends, growth factors and opportunities
- 6.5.4.3.2 Market size and forecast, by Test Type
- 6.5.4.3.3 Market size and forecast, by End User
- 6.5.4.4 Rest of LAMEA
- 6.5.4.4.1 Key market trends, growth factors and opportunities
- 6.5.4.4.2 Market size and forecast, by Test Type
- 6.5.4.4.3 Market size and forecast, by End User
CHAPTER 7: COMPETITIVE LANDSCAPE
- 7.1. Introduction
- 7.2. Top winning strategies
- 7.3. Product Mapping of Top 10 Player
- 7.4. Competitive Dashboard
- 7.5. Competitive Heatmap
- 7.6. Top player positioning, 2021
CHAPTER 8: COMPANY PROFILES
- 8.1 MP Biomedicals LLP
- 8.1.1 Company overview
- 8.1.2 Key Executives
- 8.1.3 Company snapshot
- 8.1.4 Operating business segments
- 8.1.5 Product portfolio
- 8.1.6 Business performance
- 8.1.7 Key strategic moves and developments
- 8.2 F. Hoffmann-La Roche Ltd.
- 8.2.1 Company overview
- 8.2.2 Key Executives
- 8.2.3 Company snapshot
- 8.2.4 Operating business segments
- 8.2.5 Product portfolio
- 8.2.6 Business performance
- 8.2.7 Key strategic moves and developments
- 8.3 Altona Diagnostics
- 8.3.1 Company overview
- 8.3.2 Key Executives
- 8.3.3 Company snapshot
- 8.3.4 Operating business segments
- 8.3.5 Product portfolio
- 8.3.6 Business performance
- 8.3.7 Key strategic moves and developments
- 8.4 PerkinElmer, Inc
- 8.4.1 Company overview
- 8.4.2 Key Executives
- 8.4.3 Company snapshot
- 8.4.4 Operating business segments
- 8.4.5 Product portfolio
- 8.4.6 Business performance
- 8.4.7 Key strategic moves and developments
- 8.5 Dia.Pro - Diagnostic Bioprobes s.r.l
- 8.5.1 Company overview
- 8.5.2 Key Executives
- 8.5.3 Company snapshot
- 8.5.4 Operating business segments
- 8.5.5 Product portfolio
- 8.5.6 Business performance
- 8.5.7 Key strategic moves and developments
- 8.6 Primerdesign Ltd
- 8.6.1 Company overview
- 8.6.2 Key Executives
- 8.6.3 Company snapshot
- 8.6.4 Operating business segments
- 8.6.5 Product portfolio
- 8.6.6 Business performance
- 8.6.7 Key strategic moves and developments
- 8.7 Mikrogen GmbH
- 8.7.1 Company overview
- 8.7.2 Key Executives
- 8.7.3 Company snapshot
- 8.7.4 Operating business segments
- 8.7.5 Product portfolio
- 8.7.6 Business performance
- 8.7.7 Key strategic moves and developments
- 8.8 Fortress Diagnostics
- 8.8.1 Company overview
- 8.8.2 Key Executives
- 8.8.3 Company snapshot
- 8.8.4 Operating business segments
- 8.8.5 Product portfolio
- 8.8.6 Business performance
- 8.8.7 Key strategic moves and developments
- 8.9 ELITechGroup
- 8.9.1 Company overview
- 8.9.2 Key Executives
- 8.9.3 Company snapshot
- 8.9.4 Operating business segments
- 8.9.5 Product portfolio
- 8.9.6 Business performance
- 8.9.7 Key strategic moves and developments
- 8.10 Beijing Wantai Biolog Pha Ent Co Ltd
- 8.10.1 Company overview
- 8.10.2 Key Executives
- 8.10.3 Company snapshot
- 8.10.4 Operating business segments
- 8.10.5 Product portfolio
- 8.10.6 Business performance
- 8.10.7 Key strategic moves and developments